휴메딕스

200670KOSDAQ의약품 제조업

66.9 / 100

Reference Date: 2026-07-24

Financial Score33.5 / 40

News Sentiment19.4 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Declined 7.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HumeDx operates in two main business segments: the Aesthetic Division, producing fillers, botulinum toxin, cosmetics, and medical devices, and the CMO Division, specializing in specialty pharmaceuticals, osteoarthritis treatments, and raw material production. The company leverages its proprietary HI (High molecular Ideal reticulated matrix) technology to develop long-lasting fillers and high-performance cosmetics using pharmaceutical-grade HA and PDRN.

Number of Employees

377people

Average Salary

56.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.48Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR

0.95Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

19.61Industry Average 4.017.0Point

4.9x industry avg (excellent)

Debt Ratio

1.15Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 17.6% (improving, 3yr)

Detailed News Sentiment

15 totalPositive 13Neutral 2Negative 0Average Sentiment Score 77.7

Positive
"제조부터 유통까지"…휴메딕스·도움주식회사 '맞손'
휴메딕스와 도움주식회사 간의 제조 및 위탁 계약 체결로 협력 강화 기대.
Positive
휴메딕스-도움 '아르케' 제조 위수탁 계약
휴메딕스와 도움 간의 '아르케' 제조 위수탁 계약 체결로 인해 생산 효율성 향상과 협력 강화 기대.
Positive
휴온스그룹, 보툴리눔 톡신 ‘휴톡스’ 中 품목허가 획득 이어 공식 .....
휴메딕스의 보툴리눔 톡신 '휴톡스'가 중국 시장 진출을 성공적으로 완료함으로써 긍정적인 시장 반응을 이끌어냈다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 25,250Won52-week high 72,70052-week low 24,150

1-month return1.0Point

1m -7.85% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0